Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Armodafinil and lifestyle diet trial for obstructive sleep apnea with obesity
ACTRN12611000847910Phase 3Completed
- Sponsor
- Woolcock Institute of Medical Research
- Start
- Jul 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of armodafinil in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity (4 arms), sponsored by Woolcock Institute of Medical Research. Primary endpoints: Improvement in simulated driving ability at 9 months and Loss of fat mass at 12 months. Started Jul 2012; status: completed.
02
Drugs
armodafinil
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on ACTRN12611000847910.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000847910.